The Health Ministry will not respond to pharma manufacturers’ calls to define what chronic diseases are, Al Mal said. It is “a nonsensical request,” the ministry said, as this should be the companies’ basic knowledge, according to Al Mal. Pharma producers haveasked the government to define for them what it believes to be a treatment for chronic illness as those will not see their prices changed. Separately, pharma producers are reportedly saying that only with the medication price increases agreed to by the government will they be able to reach a cumulative sales volume of EGP 50 bn in 2017, Al Borsa reported. The pharma division at the Federation of Egyptian Industries expects the sector’s sales to have recorded EGP 40 bn in 2016.
More from Enterprise
Banque du Caire opens its IPO books at EGP 4.82-5.30 a share, with room to grow to 45%
The state-owned lender could raise up to EGP 36.4 bn,…
Inside the financing of Egypt’s IPP boom
The contracts and the resources are proven, so the open…
FRA and EGX eye law change to let LLCs and partnerships set up investment funds
Regulators want to keep Egyptian money from setting up funds…
Egyptian-UK fintech Zeal raises USD 10 mn to back expansion plans
The London-based, Egyptian-founded fintech is preparing to activate its loyalty…